Abbott acquisition of Exact Sciences set to close on March 23, 2026

Abbott announced that it expects to close the acquisition of Exact Sciences on March 23, 2026. The announcement follows receipt of all regulatory clearances necessary for closing. The transaction enables Abbott to enter cancer screening and diagnostics segments. Together with Exact Sciences, Abbott will accelerate innovation and expand access to diagnostics that help more people detect and manage cancer at its earliest stages. Abbott chairman and chief executive officer Robert B. Ford said proactively shaping the portfolio to anticipate future medical needs remains at the core of the strategic framework. He said the addition of Exact Sciences enhances the company's growth profile and strengthens its leadership in diagnostics. Exact Sciences is a leader in cancer screening, precision oncology and genetic testing. The company helps detect cancer earlier, guide treatment decisions and monitor for recurrence. The transaction is expected to add approximately 3 billion dollars of incremental sales in 2026. It will accelerate Abbott's 2026 sales growth by approximately 0.5 percent and dilute adjusted earnings per share by approximately 0.20 dollars.